Teva’s NTE Strategy Initially Emphasizes Pain, Glaucoma, Schizophrenia
This article was originally published in The Pink Sheet Daily
Teva seeks to leverage its “new therapeutic entities” strategy devised under the regime of now-departed CEO Jeremy Levin in order to bolster revenues as it maneuvers through the patent expiration of its most profitable product, Copaxone, in May 2014.
You may also be interested in...
A More Disciplined Teva Gets Lukewarm Reception From Street
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?
iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements
Advisory committee to discuss proposed changes to isotretinoin REMS to minimize burden and treatment delays while preventing risk of fetal exposure. Agency recommends against at-home pregnancy tests.
Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS
Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.